AllianceBernstein argues healthcare investors should look beyond large pharmaceutical stocks to capture the sector’s broader growth potential. The article shows pharma’s MSCI World Health Care weight has fallen from 82% in 2000 to 45% today, while sector leadership changes frequently.
Healthcare Investing: Finding Growth Beyond Pharmaceuticals
AllianceBernstein
Vinay Thapar, Jane Bleeg
Research
10 Pages
Key Takeaways
Pharma dominance fell: Pharma stocks fell from 82% of MSCI World Health Care in 2000 to 45% today, still dominating index exposure.
Drug risk persists: Less than 10% of drugs entering clinical trials receive FDA approval, making concentrated pharma exposure inherently binary.
Leadership rotates: Pharmaceuticals led healthcare only once in the past decade, while equipment and life-science tools often led returns.